Gastroenterology Group Practice, Brain-Gut Research Group, Bern, Switzerland.
Aliment Pharmacol Ther. 2013 Jun;37(11):1074-83. doi: 10.1111/apt.12306. Epub 2013 Apr 9.
The association of fructose and lactose intolerance and malabsorption with the symptoms of different functional gastrointestinal disorders (FGID) remains unclear.
To investigate the prevalence of fructose and lactose intolerance (symptom induction) and malabsorption and their association with clinical gastrointestinal (GI) as well as non-GI symptoms in FGID and the outcome of dietary intervention.
Fructose and lactose intolerance (defined by positive symptom index) and malabsorption (defined by increased hydrogen/methane) were determined in 1372 FGID patients in a single centre using breath testing. Results were correlated with clinical symptoms in different FGID Rome III subgroups. The effectiveness of a targeted saccharide-reduced diet was assessed after 6-8 weeks.
Intolerance prevalence across all FGIDs was 60% to fructose, 51% to lactose and 33% to both. Malabsorption occurred in 45%, 32% and 16% respectively. There were no differences in intolerance or malabsorption prevalence between FGID subgroups. FGID symptoms correlated with symptoms evoked during testing (r = 0.35-0.61. P < 0.0001), but not with malabsorption. Non-GI symptoms occurred more commonly in patients with intolerances. Methane breath levels were not associated with constipation using several cut-off thresholds. Adequate symptom relief was achieved in >80% of intolerant patients, irrespective of malabsorption.
Fructose and lactose intolerances are common in FGID and associated with increased non-GI symptoms, but not with specific FGID subtypes. Symptoms experienced during breath testing, but not malabsorption, correlate with FGID symptoms. Effective symptom relief with dietary adaptation is not associated with malabsorption. Mechanisms relating to the generation of GI and non-GI symptoms due to lactose and fructose in FGID need to be explored further.
果糖和乳糖不耐受和吸收不良与不同功能性胃肠疾病(FGID)的症状之间的关联仍不清楚。
研究果糖和乳糖不耐受(症状诱导)和吸收不良的患病率及其与 FGID 中临床胃肠道(GI)和非 GI 症状的关系,以及饮食干预的结果。
在一个中心使用呼吸测试对 1372 例 FGID 患者进行果糖和乳糖不耐受(通过阳性症状指数定义)和吸收不良(通过增加氢/甲烷定义)的测定。结果与不同 FGID Rome III 亚组的临床症状相关。在 6-8 周后评估针对特定碳水化合物减少饮食的效果。
所有 FGID 中不耐受的患病率为 60%果糖,51%乳糖和 33%果糖和乳糖。吸收不良分别发生在 45%、32%和 16%的患者中。FGID 亚组之间不耐受或吸收不良的患病率没有差异。FGID 症状与测试期间诱发的症状相关(r = 0.35-0.61,P <0.0001),但与吸收不良无关。不耐受患者更常见非 GI 症状。甲烷呼气水平与几种截止阈值的便秘无关。无论是否存在吸收不良,不耐受患者中有超过 80%的患者症状得到充分缓解。
果糖和乳糖不耐受在 FGID 中很常见,并与增加的非 GI 症状相关,但与特定的 FGID 亚型无关。呼吸测试期间经历的症状,但不是吸收不良,与 FGID 症状相关。有效的症状缓解与饮食适应无关。需要进一步探讨 FGID 中由于乳糖和果糖引起的 GI 和非 GI 症状的发生机制。